Structure Therapeutics (NASDAQ:GPCR) Given Market Outperform Rating at Citizens Jmp

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “market outperform” rating reiterated by analysts at Citizens Jmp in a research report issued on Wednesday, Benzinga reports. They currently have a $110.00 price target on the stock. Citizens Jmp’s target price would suggest a potential upside of 172.41% from the stock’s current price.

GPCR has been the subject of a number of other reports. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research report on Friday, August 7th. Finally, Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $110.91.

Structure Therapeutics Trading Down 14.7%

Shares of NASDAQ:GPCR opened at $40.38 on Wednesday. The firm has a market cap of $2.81 billion, a PE ratio of -40.38 and a beta of -1.45. The company has a fifty day simple moving average of $50.41 and a 200 day simple moving average of $49.01. Structure Therapeutics has a 12-month low of $20.04 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts forecast that Structure Therapeutics will post -1.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC increased its stake in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the period. Sterling Capital Management LLC bought a new stake in Structure Therapeutics in the first quarter worth about $28,000. IFP Advisors Inc purchased a new position in shares of Structure Therapeutics during the second quarter valued at $46,000. State of Wyoming acquired a new stake in Structure Therapeutics during the 2nd quarter worth about $28,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth approximately $127,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.